Immatics N.V.
NASDAQ:IMTXBiotechnology
+$0.15 today
- Market cap
- $912.78M
- Beta
- 1.30
- P/E (TTM)
- -5.3
- EPS (TTM)
- -$1.59
Volume 1.57M
Average 0.46M
IMTX Total Liabilities
Everything the company owes to creditors and other parties.
Immatics N.V.NASDAQ: IMTX
Total Liabilities · Q1 FY2026 · quarter ended Mar 2026
Total liabilities falls 16.7% from a year ago
Total liabilities stood at €87.55M at the end of Q1 FY2026, down 16.7% from a year earlier and up 12.0% from the prior quarter. Over 3 fiscal years it compounded at -26.2% a year.
Context
- Total liabilities amounted to 16.1% of total assets at the end of Q1 FY2026, down 0.3 pp from a year earlier.
- Total liabilities increased in 1 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
What to watch
Whether total liabilities keeps falling in the next quarterly balance sheet after a -16.7% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Total Liabilities history
EUR · from the balance sheet
- Latest · FY2025
- 78.2M EUR
- Year-over-year change
- -35.5%
- 4-year CAGR
- -15.1%
| Period | Period end | Total Liabilities | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 78.2M | -35.5% |
| FY2024 | 2024-12-31 | 121.3M | -57.4% |
| FY2023 | 2023-12-31 | 284.88M | +46.4% |
| FY2022 | 2022-12-31 | 194.66M | +29.3% |
| FY2021 | 2021-12-31 | 150.58M | — |
Total Liabilities vs competitors
How IMTX compares with its peers on the latest reported figures
- Peers report in different currencies, so total liabilities is compared through growth and share of total assets rather than absolute size.
- Its year-over-year change of -16.7% is the 7th highest of 11, against a peer median of -12.0%.
- Total liabilities amounts to 16.1% of total assets for IMTX, versus a peer median of 38.3%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Jun 2026 | €2.58B EUR | -17.5% | -5.0% | 12.7% | |
| Mar 2026 | $678.42M USD | +4.4% | +54.0% | 63.3% | |
| Sep 2026 | $408.7M USD | -41.8% | +7.6% | 24.3% | |
| Mar 2026 | $229.27M USD | -7.5% | +22.5% | 79.3% | |
| Mar 2026 | $117.08M USD | -4.5% | -7.3% | 29.6% | |
| Mar 2026 | $105.07M USD | -14.2% | +2.0% | 52.0% | |
| Mar 2026 | €87.55M EUR | -16.7% | -26.2% | 16.1% | |
| Mar 2026 | $86.69M USD | +126.3% | +5.4% | 8.4% | |
| Mar 2026 | $76.96M USD | -17.5% | -4.2% | 21.9% | |
| Mar 2026 | $67.79M USD | -9.7% | -29.5% | 47.1% | |
| Mar 2026 | $57.31M USD | -51.1% | -38.3% | 286.6% | |
| Peer median (excluding IMTX) | — | -12.0% | -1.1% | 38.3% | |
Competitors are the stored peer set for IMTX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | 132.99M | 148.52M | 218.47M | 236.75M | 345.77M |
| Short-term Investments | 12.12M | 213.69M | 207.42M | 367.7M | 123.37M |
| Net Receivables | 2.36M | 1.11M | 5.74M | 6.75M | 6.88M |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Other Current Assets | 950K | 13.84M | 7.12M | 6.31M | 14.86M |
| Total Current Assets | 152.21M | 377.15M | 449.37M | 629.56M | 503.79M |
| Property, Plant & Equipment (Net) | 20.49M | 26.49M | 57.06M | 63.71M | 54.87M |
| Goodwill | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 1.32M | 1.63M | 1.52M | 1.63M | 1.58M |
| Long-term Investments | 0 | 0 | 0 | 0 | 0 |
| Tax Assets | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Assets | 636K | 2.55M | 2.02M | 1.25M | 1.85M |
| Total Non-current Assets | 22.44M | 30.67M | 60.6M | 66.59M | 58.3M |
| Total Assets | 174.65M | 407.82M | 509.97M | 696.15M | 562.1M |
| Account Payables | 3.01M | 4.03M | 7.67M | 10.11M | 339.86K |
| Short-term Debt | 0 | 0 | 0 | 0 | 2.76M |
| Tax Payables | 1.76M | 7.72M | 7.86M | 3.77M | 0 |
| Deferred Revenue | 50.4M | 64.96M | 100.4M | 35.91M | 15.81M |
| Other Current Liabilities | 28.04M | 17.88M | 20.48M | 4.77M | 2.81M |
| Total Current Liabilities | 95.15M | 106.45M | 156.55M | 67.99M | 42.99M |
| Long-term Debt | 0 | 0 | 0 | 0 | 0 |
| Deferred Tax Liabilities | 0 | 0 | 0 | 5.8M | 3.81M |
| Deferred Revenue (Non-current) | 48.23M | 75.76M | 115.53M | 34.16M | 18.53M |
| Other Non-current Liabilities | 68K | 42K | 115.53M | 0 | 0 |
| Total Non-current Liabilities | 55.44M | 88.2M | 128.33M | 53.32M | 35.21M |
| Total Liabilities | 150.58M | 194.66M | 284.88M | 121.3M | 78.2M |
| Common Stock | 629K | 767K | 847K | 1.22M | 1.34M |
| Retained Earnings | (537.81M) | (500.3M) | (597.29M) | (589.54M) | (785.65M) |
| Accumulated OCI | (3.95M) | (1.48M) | (1.64M) | 1.03M | (8.59M) |
| Other Stockholders Equity | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 |
| Total Equity | 24.06M | 213.16M | 225.08M | 574.84M | 483.89M |
| Total Debt | 9.85M | 14.56M | 15.4M | 16.2M | 15.63M |
| Net Debt | (123.14M) | (133.96M) | (203.07M) | (220.55M) | (330.14M) |
Immatics N.V.
NASDAQ:IMTX
Intrinsic Alpha fair value
Locked
Current Price
$6.10
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.